Peringatan Keamanan

Lutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus.

Lutropin alfa

DB00044

biotech approved

Deskripsi

Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum. In males, LH stimulates Leydig cell to produce testosterone.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Biphasic; terminal half-life is approximately 18 hours.
Volume Distribusi The steady state volume of distribution is around 10-14 L.
Klirens (Clearance) * 2 – 3 L/h [healthy female following subcutaneous administration]

Absorpsi

Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours

Metabolisme

<5% of dose excreted renally as unchanged drug.

Rute Eliminasi

Total body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally.

Interaksi Obat

0 Data
Tidak ada data.

Target Protein

Lutropin-choriogonadotropic hormone receptor LHCGR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3972
    Blanchard J: Gastrointestinal absorption. I. Mechanisms. Am J Pharm Sci Support Public Health. 1975 Sep-Oct;147(5):135-46.
  • PMID: 1122882
    Louvet JP, Harman SM, Ross GT: Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats. Endocrinology. 1975 May;96(5):1179-86.
  • PMID: 11476792
    Nielsen MS, Barton SD, Hatasaka HH, Stanford JB: Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril. 2001 Aug;76(2):384-7.
  • PMID: 20161981
    Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17.
  • PMID: 18627209
    Dhillon S, Keating GM: Lutropin alfa. Drugs. 2008;68(11):1529-40.

Contoh Produk & Brand

Produk: 19 • International brands: 0
Produk
  • Luveris
    Kit • 82.5 [iU]/1mL • Subcutaneous • US • Approved
  • Luveris
    Powder, for solution • 75 unit / vial • Subcutaneous • Canada • Approved
  • Luveris
    Solution • 450 unit / 0.72 mL • Subcutaneous • Canada • Approved
  • Luveris
    Injection, powder, for solution • 75 IU • Subcutaneous • EU • Approved
  • Luveris
    Injection, powder, for solution • 75 IU • Subcutaneous • EU • Approved
  • Luveris
    Injection, powder, for solution • 75 IU • Subcutaneous • EU • Approved
  • Luveris
    Injection, powder, for solution • 75 IU • Subcutaneous • EU • Approved
  • Luveris
    Injection, powder, for solution • 75 IU • Subcutaneous • EU • Approved
Menampilkan 8 dari 19 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul